Sunday, December 26, 2021 11:31:27 PM
dehaze
search
close
SIGN IN
?
U.S. Severe Oral Mucositis Market to Surpass US$ 267.7 Million by 2028, Says Coherent Market Insights (CMI)
August 12, 2021 09:20 ET| Source: CMI
SEATTLE, Aug. 12, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S. Severe Oral Mucositis Market is estimated to be valued at US$ 78.5 million in 2021 and is expected to exhibit a CAGR of 19.2% during the forecast period (2021-2028).
Key Trends and Analysis of the U.S. Severe Oral Mucositis Market:
Key players operating in the market are focusing on the development of treatments for severe oral mucositis, which is expected to offer lucrative opportunities for the market players to launch novel products in the market. For instance, in June 2020, Soligenix, Inc. announced that it completed patient enrolment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients.
For instance, in February 2020, Galera Therapeutics, Inc. announced full tumor results of the two year follow up of patients with head and neck cancer treated with avasopasem manganese (GC4419), which is Galera’s lead product candidate for severe oral mucositis (SOM) and is curently in a Phase 2b clinical trial.
Key Market Takeaways:
The U.S. severe oral mucositis market is expected to exhibit a CAGR of 19.2% during the forecast period due to increasing prevalence of head and neck cancer in the U.S., which is expected to boost the U.S. severe oral mucositis market in 2028. For instance, according to the Centers for Disease Control and Prevention report, around 650,000 cancer patients receive chemotherapy in an outpatient setting each year in the U.S. and according to a consensus about 500,000 cases of OM occur in the U.S. every year.
Recent GRTX News
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:06:04 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/20/2024 11:57:58 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:39 PM
- Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/13/2023 07:24:56 PM
- Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial • Dow Jones News • 10/31/2023 12:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 11:10:53 AM
- Galera Announces Receipt of Type A Meeting Minutes and Strategic Update • GlobeNewswire Inc. • 10/31/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 11:24:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 09:12:53 PM
- Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:10:28 AM
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 08/14/2023 11:00:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:00:58 PM
- Stocks to Watch: Applovin, Disney, Galera Therapeutics • Dow Jones News • 08/10/2023 12:10:00 AM
- Galera Therapeutics to Reduce Workforce by 70% to Extend Cash Runway • Dow Jones News • 08/09/2023 09:23:00 PM
- Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese • GlobeNewswire Inc. • 08/09/2023 08:31:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 08:11:02 PM
- Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting • GlobeNewswire Inc. • 06/05/2023 06:15:00 PM
- Galera Therapeutics Gets Orphan Drug Designation for Rucosopasem • Dow Jones News • 05/18/2023 12:44:00 PM
- Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer • GlobeNewswire Inc. • 05/18/2023 12:00:00 PM
- Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 05/11/2023 11:00:00 AM
FEATURED Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM
Avant Technologies Begins Development on Next-Generation AI-Driven Resource Allocation Solution • AVAI • Apr 16, 2024 8:00 AM
UC Asset Expected to Report $0.03/share Net Profit for 2023 • UCASU • Apr 11, 2024 10:00 AM
Kona Gold Beverages & Apple Rush Co. Execute Joint Venture & Manufacturing Agreement • APRU • Apr 11, 2024 9:40 AM